Denali Therapeutics Q2 Earnings Call Highlights

Impact · against what's priced in

DNLI is seeing a positive initial commercial ramp for AVLAYAH and a strengthened cash position, though pipeline delays for DNL593 offset some gains. The strong Q3 revenue guidance suggests a successful launch trajectory that likely exceeds base expectations.

DNLI+0.50

No priced-in read yet

In context

The jump in projected Q3 revenue to $10-$12 million from $3.6 million in Q2, combined with $1.1 billion in liquidity, provides a strong immediate catalyst, though the DNL593 data delay to 2027 is a negative offset.

Read from the article alone

• earnings▲6%
• guidance
• healthcare
• biotech
• DNLI
• LZVNY
• alzheimers
• clinical trials
• drug launch
• fda